Previous studies have indicated that a deletion on the short arm of chromosome 1 negatively predicts survival in patients with multiple myeloma (MM). Due to the small sample size in each study, we performed this meta-analysis to comprehensively investigate the association between the 1p deletion and survival in patients with MM.

Methods

A literature search was conducted in both foreign and Chinese databases, including SinoMed, CNKI, Wanfang, PubMed, EMBASE, and Scopus. Hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS) in 11 eligible articles were extracted or calculated to analyze the pooled HR, which was estimated by fixed-effect or random-effect models based on the heterogeneity between included articles. A subgroup analysis and a meta-regression were conducted, and Galbraith plots were generated to examine any possible heterogeneity.

Results

The HRs for OS were available in nine articles, whereas five articles discussed HRs for PFS. The HR with 95%CI was 1.989 (95%CI 1.522–2.600, P = 0.017, I² = 57.1%) when comparing the OS of patients with 1p deletion with the OS of those without this deletion. For PFS, 1p deletion still predicted a poor prognosis (HR 2.11, 95%CI 1.54–2.88, P = 0.292, I² = 19.3%). Moreover, the subgroup analysis suggested that either the deleted gene on 1p or techniques for detecting chromosome abnormalities contributed to the heterogeneity, which was partially consistent with the results derived from a meta-regression analysis and the Galbraith plot method.

Conclusion

Our meta-analysis provides globally quantifiable confirmation of the adverse prognostic role of 1p deletion in OS and PFS for patients with MM.

References

1Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.
10.4065/78.1.21
PubMed Web of Science® Google Scholar
2Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev 2012; 12: 335–48.
10.1038/nrc3257
CAS Web of Science® Google Scholar
3Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfão A. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366–71.
10.1182/blood.V91.9.3366
CAS PubMed Web of Science® Google Scholar
4Yuregir OO, Sahin FI, Yilmaz Z, Kizilkilic E, Karakus S, Ozdogu H. Fluorescent in situ hybridization studies in multiple myeloma. Hematology 2009; 14: 90–4.
10.1179/102453309X385250
PubMed Web of Science® Google Scholar
5Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127: 280–4.
10.1111/j.1365-2141.2004.05199.x
CAS PubMed Web of Science® Google Scholar
6Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 1–16.
10.1186/1745-6215-8-16
PubMed Web of Science® Google Scholar
7Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
Google Scholar
8Yan L, Zaixing Y, Renqian Z. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56: 1409–17.
10.1002/hep.25788
PubMed Web of Science® Google Scholar
9Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.
10.1002/sim.1186
PubMed Google Scholar
10Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17: 7776–84.
10.1158/1078-0432.CCR-11-1791
CAS PubMed Web of Science® Google Scholar
11Jiang N, Qi C, Trieu Y, Reece D, Chang H. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1790–5.
10.1016/j.bbmt.2011.05.009
CAS PubMed Web of Science® Google Scholar
12Chang H, Qi X, Jiang A, Xu W, Young T, Reece D. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010; 45: 117–21.
10.1038/bmt.2009.107
CAS PubMed Web of Science® Google Scholar
13Hong C, Jiang A, Qi C, Trieu Y, Chen C, Reece D. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma 2010; 51: 2084–91.
10.3109/10428194.2010.524325
CAS PubMed Web of Science® Google Scholar
14Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24: 833–42.
10.1038/leu.2010.21
CAS PubMed Web of Science® Google Scholar
15Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Nicholas JD, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008; 14: 6033–41.
10.1158/1078-0432.CCR-08-0347
CAS PubMed Web of Science® Google Scholar
16Tian EM, Borset M, Barlogie B. Interphase FISH of Chromosome 1 And 13 in Newly Diagnosed Myeloma and the Disease Prognosis. 2nd International Conference on Biomedical Engineering and Informatics. 2009. Tianjin Univ Technol, Tianjin, China: IEEE, 345 E 47th St, New York, NY 10017, USA.
Google Scholar
17Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Gregor E. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007; 136: 615–23.
10.1111/j.1365-2141.2006.06481.x
CAS PubMed Web of Science® Google Scholar
18Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem C, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066–72.
10.1016/j.bbmt.2007.05.014
PubMed Web of Science® Google Scholar
19Panani AD, Ferti AD, Papaxoinis C, Raptis SA, Roussos Ch. Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor. Anticancer Res 2004; 24: 4141–6.
PubMed Web of Science® Google Scholar
20Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Dávila R, González-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427–36.
10.1038/sj.leu.2402797
CAS PubMed Web of Science® Google Scholar
21Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 375–92.
10.1023/A:1014778713034
CAS PubMed Web of Science® Google Scholar
22Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20.
10.1200/JCO.2005.04.242
PubMed Web of Science® Google Scholar
23Egger M, Smith GD, Schneider M, Ghristoph M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
10.1136/bmj.315.7109.629
CAS PubMed Web of Science® Google Scholar
24Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RKM, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116: e56–65.
10.1182/blood-2010-04-279596
CAS PubMed Web of Science® Google Scholar
25Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002; 16: 127–34.
10.1038/sj.leu.2402328
CAS PubMed Web of Science® Google Scholar
26Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity 1997; 6: 47–56.
10.1016/S1074-7613(00)80241-1
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume36, Issue5

October 2014

Pages 555-565

Prognostic value of 1p deletion for multiple myeloma: a meta-analysis

Summary

Introduction

Methods

Results

Conclusion

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Prognostic value of 1p deletion for multiple myeloma: a meta-analysis

Summary

Introduction

Methods

Results

Conclusion

References

Citing Literature

References

Related

Information